Neurocrine AI Stock Analysis
Neurocrine (1NBIX) AI Stock Analysis
Neurocrine
(Milan:1NBIX)
No summary available
Neurocrine (1NBIX) vs. iShares MSCI Italy ETF (EWI)
- Market Cap
- EUR 17.65B
- Dividend Yield
- ―
- Average Volume (3M)
- 46
- Price to Earnings (P/E)
- 25.0
- Beta (1Y)
- 0.39
- Revenue Growth
- 31.81%
- EPS Growth
- 57.79%
- Country
- Italy
- Employees
- 2,500
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Neurocrine Business Overview & Revenue Model
Company Description
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and market...
Neurocrine Earnings Call Summary
The call was strongly positive, supported by record third-quarter revenue and profitability, more than 40% year-over-year sales growth, growth across all three commercial products, increased INGREZZA guidance, substantial cash generation, and a broad pipeline with multiple 2027 catalysts. The main challenges were INGREZZA's expected fourth-quarter order-timing reversal and pricing headwinds, delayed VYKAT XR growth amid recent external events and ongoing safety and education work, and the discontinuation of NBI-'986. Highlights significantly outweighed lowlights.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Neurocrine raised full year INGREZZA guidance to $2.9 billion to $2.925 billion, with 2026 prescription growth expected to be in the high-teens; for the fourth quarter, underlying TRx growth is expected to be somewhere in the mid-teens. For 2027, the company expects continued double-digit INGREZZA volume growth to more than offset anticipated mid- to high single-digit net pricing headwinds, with roughly mid- to high single-digit price concession, and expects 2027 access to be at least as good as this year, when about 70% of Medicare lives were covered under contracting executed in 2025; formal 2027 sales guidance will be provided in February. For VYKAT XR, the company anticipates a return to growth, but it might be a little bit more delayed, and said every quarter it wants to see more patients on than the prior quarter. The company plans to initiate a VYKAT XR study in 2027 in people with PWS and complex health issues, expects Phase III data readouts for osavampator in major depressive disorder and direclidine in schizophrenia in 2027, and remains on track to deliver 6 Phase Is, along with 5 new Phase II starts this year.
Neurocrine Risk Analysis
Neurocrine disclosed 51 risk factors in its most recent earnings report. Neurocrine reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
3 New RisksNeurocrine Peers Comparison
Overall Rating
HRMY77Outperform
ACAD72Outperform
PRAX71Outperform
AXSM47Neutral
XENE46Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HRMY | 77Outperform | $1.97B | 11.11 | 18.55% | ― | 19.79% | -4.89% |
| ACAD | 72Outperform | $3.16B | 8.62 | 28.03% | ― | 14.82% | 36.49% |
| PRAX | 71Outperform | $9.44B | -27.00 | -29.41% | ― | -100.00% | 0.75% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AXSM | 47Neutral | $7.42B | -48.77 | -189.73% | ― | 54.16% | 34.51% |
| XENE | 46Neutral | $4.07B | -8.96 | -39.80% | ― | -100.00% | -21.09% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IT:1NBIX | Neurocrine Biosciences | 154.95 | 27.50 | 21.58% | |
| ACAD | ACADIA Pharmaceuticals Inc. | 18.37 | -5.65 | -23.52% | |
| XENE | Xenon Pharmaceuticals | 42.10 | 1.34 | 3.29% | |
| AXSM | Axsome Therapeutics Inc. | 149.24 | 9.55 | 6.84% | |
| HRMY | Harmony Biosciences Holdings, Inc. | 34.22 | 0.19 | 0.56% | |
| PRAX | Praxis Precision Medicines, Inc. | 346.21 | 159.79 | 85.72% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.